Cargando…
Clot Waveform Analysis for Hemostatic Abnormalities
Clot waveform analysis (CWA) observes changes in transparency in a plasma sample based on clotting tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). Evidence indicates that not only an abnormal waveform but also peak times and heights in deriv...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Laboratory Medicine
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345169/ https://www.ncbi.nlm.nih.gov/pubmed/37387486 http://dx.doi.org/10.3343/alm.2023.43.6.531 |
_version_ | 1785073026485714944 |
---|---|
author | Wada, Hideo Shiraki, Katsuya Matsumoto, Takeshi Shimpo, Hideto Shimaoka, Motomu |
author_facet | Wada, Hideo Shiraki, Katsuya Matsumoto, Takeshi Shimpo, Hideto Shimaoka, Motomu |
author_sort | Wada, Hideo |
collection | PubMed |
description | Clot waveform analysis (CWA) observes changes in transparency in a plasma sample based on clotting tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). Evidence indicates that not only an abnormal waveform but also peak times and heights in derivative curves of CWA are useful for the evaluation of hemostatic abnormalities. Modified CWA, including the PT with APTT reagent, dilute PT (small amount of tissue factor [TF]-induced clotting factor IX [FIX] activation; sTF/FIXa), and dilute TT, has been proposed to evaluate physiological or pathological hemostasis. We review routine and modified CWA and their clinical applications. In CWA-sTF/FIXa, elevated peak heights indicate hypercoagulability in patients with cancer or thrombosis, whereas prolonged peak times indicate hypocoagulability in several conditions, including clotting factor deficiency and thrombocytopenia. CWA-dilute TT reflects the thrombin burst, whereas clot-fibrinolysis waveform analysis reflects both hemostasis and fibrinolysis. The relevance and usefulness of CWA-APTT and modified CWA should be further investigated in various diseases. |
format | Online Article Text |
id | pubmed-10345169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean Society for Laboratory Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-103451692023-07-15 Clot Waveform Analysis for Hemostatic Abnormalities Wada, Hideo Shiraki, Katsuya Matsumoto, Takeshi Shimpo, Hideto Shimaoka, Motomu Ann Lab Med Review Article Clot waveform analysis (CWA) observes changes in transparency in a plasma sample based on clotting tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). Evidence indicates that not only an abnormal waveform but also peak times and heights in derivative curves of CWA are useful for the evaluation of hemostatic abnormalities. Modified CWA, including the PT with APTT reagent, dilute PT (small amount of tissue factor [TF]-induced clotting factor IX [FIX] activation; sTF/FIXa), and dilute TT, has been proposed to evaluate physiological or pathological hemostasis. We review routine and modified CWA and their clinical applications. In CWA-sTF/FIXa, elevated peak heights indicate hypercoagulability in patients with cancer or thrombosis, whereas prolonged peak times indicate hypocoagulability in several conditions, including clotting factor deficiency and thrombocytopenia. CWA-dilute TT reflects the thrombin burst, whereas clot-fibrinolysis waveform analysis reflects both hemostasis and fibrinolysis. The relevance and usefulness of CWA-APTT and modified CWA should be further investigated in various diseases. Korean Society for Laboratory Medicine 2023-11-01 2023-06-30 /pmc/articles/PMC10345169/ /pubmed/37387486 http://dx.doi.org/10.3343/alm.2023.43.6.531 Text en © Korean Society for Laboratory Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Wada, Hideo Shiraki, Katsuya Matsumoto, Takeshi Shimpo, Hideto Shimaoka, Motomu Clot Waveform Analysis for Hemostatic Abnormalities |
title | Clot Waveform Analysis for Hemostatic Abnormalities |
title_full | Clot Waveform Analysis for Hemostatic Abnormalities |
title_fullStr | Clot Waveform Analysis for Hemostatic Abnormalities |
title_full_unstemmed | Clot Waveform Analysis for Hemostatic Abnormalities |
title_short | Clot Waveform Analysis for Hemostatic Abnormalities |
title_sort | clot waveform analysis for hemostatic abnormalities |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345169/ https://www.ncbi.nlm.nih.gov/pubmed/37387486 http://dx.doi.org/10.3343/alm.2023.43.6.531 |
work_keys_str_mv | AT wadahideo clotwaveformanalysisforhemostaticabnormalities AT shirakikatsuya clotwaveformanalysisforhemostaticabnormalities AT matsumototakeshi clotwaveformanalysisforhemostaticabnormalities AT shimpohideto clotwaveformanalysisforhemostaticabnormalities AT shimaokamotomu clotwaveformanalysisforhemostaticabnormalities |